KPRX insider trading
NasdaqCM HealthcareKIORA PHARMACEUTICALS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About KIORA PHARMACEUTICALS INC
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Company website: www.kiorapharma.com
KPRX insider activity at a glance
FilingIQ has scored 43 insider transactions for KPRX since Oct 21, 2021. The most recent filing in our index is dated Apr 1, 2026.
Across the full history, 10 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on KPRX insider trades is 60.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest KPRX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for KPRX?
- FilingIQ tracks 43 Form 4 insider transactions for KPRX (KIORA PHARMACEUTICALS INC), covering filings from Oct 21, 2021 onwards. 11 of those were filed in the last 90 days.
- Are KPRX insiders net buyers or net sellers?
- Across the full Form 4 history for KPRX, 10 transactions (23%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does KPRX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is KPRX in?
- KIORA PHARMACEUTICALS INC (KPRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.66M.
Methodology & sources
Every KPRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.